Overview

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Status:
Recruiting

Trial end date:
2023-12-05

Target enrollment:

Participant gender:

Summary

This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion using a modified weekly schedule.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

Hoffmann-La Roche